Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age

IntroductionAn imbalance in angiotensin (Ang) peptides could contribute to the pathophysiology of preeclampsia (PE) and poor fetal growth.MethodsWe measured maternal plasma levels of Ang peptides and converting enzymes in non-pregnant women (n = 10), in normal pregnant women (n = 59), women deliveri...

Full description

Bibliographic Details
Main Authors: Sonia Tamanna, Vicki L. Clifton, Kym Rae, Dirk F. van Helden, Eugenie R. Lumbers, Kirsty G. Pringle
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Physiology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fphys.2020.590787/full
id doaj-7a770936bd464895ae9a007a91dcbd98
record_format Article
spelling doaj-7a770936bd464895ae9a007a91dcbd982020-11-25T02:23:32ZengFrontiers Media S.A.Frontiers in Physiology1664-042X2020-09-011110.3389/fphys.2020.590787590787Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational AgeSonia Tamanna0Sonia Tamanna1Sonia Tamanna2Vicki L. Clifton3Vicki L. Clifton4Kym Rae5Dirk F. van Helden6Eugenie R. Lumbers7Eugenie R. Lumbers8Eugenie R. Lumbers9Kirsty G. Pringle10Kirsty G. Pringle11Kirsty G. Pringle12Priority Research Centre for Reproductive Sciences, University of Newcastle, Newcastle, NSW, AustraliaSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaPregnancy and Reproduction Program, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, AustraliaRobinson Research Institute, School of Medicine, University of Adelaide, Adelaide, SA, AustraliaMater Medical Research Institute and Translational Research Institute, University of Queensland, Brisbane, QLD, AustraliaMater Medical Research Institute and Translational Research Institute, University of Queensland, Brisbane, QLD, AustraliaSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaPriority Research Centre for Reproductive Sciences, University of Newcastle, Newcastle, NSW, AustraliaSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaPregnancy and Reproduction Program, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, AustraliaPriority Research Centre for Reproductive Sciences, University of Newcastle, Newcastle, NSW, AustraliaSchool of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Newcastle, NSW, AustraliaPregnancy and Reproduction Program, Hunter Medical Research Institute, University of Newcastle, Newcastle, NSW, AustraliaIntroductionAn imbalance in angiotensin (Ang) peptides could contribute to the pathophysiology of preeclampsia (PE) and poor fetal growth.MethodsWe measured maternal plasma levels of Ang peptides and converting enzymes in non-pregnant women (n = 10), in normal pregnant women (n = 59), women delivering small for gestational age babies (SGA, n = 25) across gestation (13–36 weeks) and in women with PE (n = 14) in their third trimester.ResultsPlasma ACE, ACE2, and Ang-(1-7) levels, and ACE2 activity were significantly higher in normal pregnant women compared with non-pregnant women; neprilysin (NEP) levels were not changed. In SGA pregnancies, ACE and ACE2 levels were higher in early-mid pregnancy compared with normal pregnant women. In women with PE, plasma ACE, ACE2, NEP, and Ang-(1-7) levels and ACE2 activity were lower than levels in normal pregnant women.ConclusionThe higher plasma ACE2 levels and activity in pregnancy could be driving the higher Ang-(1-7) levels. The early gestation increases in ACE and ACE2 levels in SGA pregnancies highlights the possibility that these enzymes could be used as potential early biomarkers of poor fetal growth. In women with PE, the reduced ACE2 and NEP levels at term, could be contributing to the reduction in Ang-(1-7) levels. These findings suggest that dysfunctional relationships between two key enzymes in the circulating RAS are involved in the pathogenesis of PE and SGA. Since soluble ACE2 can prevent binding of the novel coronavirus, SARS-CoV-2, to membrane bound ACE2, the interplay between ACE2 and the coronavirus and its impact in pregnancy requires further investigation.https://www.frontiersin.org/article/10.3389/fphys.2020.590787/fullangiotensin converting enzyme 2 (ACE2)angiotensin peptidespreeclampsiapregnancysmall for gestational age
collection DOAJ
language English
format Article
sources DOAJ
author Sonia Tamanna
Sonia Tamanna
Sonia Tamanna
Vicki L. Clifton
Vicki L. Clifton
Kym Rae
Dirk F. van Helden
Eugenie R. Lumbers
Eugenie R. Lumbers
Eugenie R. Lumbers
Kirsty G. Pringle
Kirsty G. Pringle
Kirsty G. Pringle
spellingShingle Sonia Tamanna
Sonia Tamanna
Sonia Tamanna
Vicki L. Clifton
Vicki L. Clifton
Kym Rae
Dirk F. van Helden
Eugenie R. Lumbers
Eugenie R. Lumbers
Eugenie R. Lumbers
Kirsty G. Pringle
Kirsty G. Pringle
Kirsty G. Pringle
Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
Frontiers in Physiology
angiotensin converting enzyme 2 (ACE2)
angiotensin peptides
preeclampsia
pregnancy
small for gestational age
author_facet Sonia Tamanna
Sonia Tamanna
Sonia Tamanna
Vicki L. Clifton
Vicki L. Clifton
Kym Rae
Dirk F. van Helden
Eugenie R. Lumbers
Eugenie R. Lumbers
Eugenie R. Lumbers
Kirsty G. Pringle
Kirsty G. Pringle
Kirsty G. Pringle
author_sort Sonia Tamanna
title Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
title_short Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
title_full Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
title_fullStr Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
title_full_unstemmed Angiotensin Converting Enzyme 2 (ACE2) in Pregnancy: Preeclampsia and Small for Gestational Age
title_sort angiotensin converting enzyme 2 (ace2) in pregnancy: preeclampsia and small for gestational age
publisher Frontiers Media S.A.
series Frontiers in Physiology
issn 1664-042X
publishDate 2020-09-01
description IntroductionAn imbalance in angiotensin (Ang) peptides could contribute to the pathophysiology of preeclampsia (PE) and poor fetal growth.MethodsWe measured maternal plasma levels of Ang peptides and converting enzymes in non-pregnant women (n = 10), in normal pregnant women (n = 59), women delivering small for gestational age babies (SGA, n = 25) across gestation (13–36 weeks) and in women with PE (n = 14) in their third trimester.ResultsPlasma ACE, ACE2, and Ang-(1-7) levels, and ACE2 activity were significantly higher in normal pregnant women compared with non-pregnant women; neprilysin (NEP) levels were not changed. In SGA pregnancies, ACE and ACE2 levels were higher in early-mid pregnancy compared with normal pregnant women. In women with PE, plasma ACE, ACE2, NEP, and Ang-(1-7) levels and ACE2 activity were lower than levels in normal pregnant women.ConclusionThe higher plasma ACE2 levels and activity in pregnancy could be driving the higher Ang-(1-7) levels. The early gestation increases in ACE and ACE2 levels in SGA pregnancies highlights the possibility that these enzymes could be used as potential early biomarkers of poor fetal growth. In women with PE, the reduced ACE2 and NEP levels at term, could be contributing to the reduction in Ang-(1-7) levels. These findings suggest that dysfunctional relationships between two key enzymes in the circulating RAS are involved in the pathogenesis of PE and SGA. Since soluble ACE2 can prevent binding of the novel coronavirus, SARS-CoV-2, to membrane bound ACE2, the interplay between ACE2 and the coronavirus and its impact in pregnancy requires further investigation.
topic angiotensin converting enzyme 2 (ACE2)
angiotensin peptides
preeclampsia
pregnancy
small for gestational age
url https://www.frontiersin.org/article/10.3389/fphys.2020.590787/full
work_keys_str_mv AT soniatamanna angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT soniatamanna angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT soniatamanna angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT vickilclifton angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT vickilclifton angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT kymrae angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT dirkfvanhelden angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT eugenierlumbers angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT eugenierlumbers angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT eugenierlumbers angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT kirstygpringle angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT kirstygpringle angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
AT kirstygpringle angiotensinconvertingenzyme2ace2inpregnancypreeclampsiaandsmallforgestationalage
_version_ 1724859114103767040